Calithera Biosciences Inc
NASDAQ:CALA
Calithera Biosciences Inc
Additional Paid In Capital
Calithera Biosciences Inc
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Calithera Biosciences Inc
NASDAQ:CALA
|
Additional Paid In Capital
$510.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Calithera Biosciences Inc's Additional Paid In Capital?
Additional Paid In Capital
510.7m
USD
Based on the financial report for Dec 31, 2022, Calithera Biosciences Inc's Additional Paid In Capital amounts to 510.7m USD.
What is Calithera Biosciences Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
11%
Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Calithera Biosciences Inc have been 6% over the past three years , 11% over the past five years .